The potential benefits of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Korantzopoulos
Panagiotis
P
Kountouris
Evaggelos
E
Siogas
Konstantinos
K
Galaris
Dimitrios
D
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D048909:Diabetes Complications / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D017202:Myocardial Ischemia / Q000150:complications / Q000188:drug therapy*; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D014292:Trimetazidine / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D000975:Antioxidants; D005227:Fatty Acids; D014665:Vasodilator Agents; D014292:Trimetazidine